| Literature DB >> 18061664 |
Massimo Breccia1, Fabiana Gentilini, Laura Cannella, Roberto Latagliata, Ida Carmosino, Annamaria Frustaci, Giuliana Alimena.
Abstract
Imatinib mesylate is a selective inhibitor of the bcr/abl, c-kit and PDGF receptor tyrosine kinases. Its ocular toxicity is little known with mild periorbital oedema being the most commonly reported side effect. We here describe our experience on ocular complications in imatinib treated Ph+ CML patients, which consisted of a wide spectrum of adverse effects ranging from periobital oedema to serious adverse events such as glaucoma.Entities:
Mesh：
Substances：
Year: 2007 PMID： 18061664 DOI： 10.1016/j.leukres.2007.10.016
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156